News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Takeda Pharmaceutical Co. Ltd. (TKPYY) Release: American Society of Clinical Oncology Presentation Highlights Results of Single Agent oral MLN9708 in Heavily Pretreated Patients with Relapsed and/or Refractory Multiple Myeloma



6/3/2013 11:04:57 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CHICAGO & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502) today reported results from a Phase 1 study evaluating the safety, tolerability, and maximum tolerated dose (MTD) of MLN9708, the first investigational oral proteasome inhibitor in clinical trials. The study evaluated once a week oral dosing of single agent MLN9708 in patients with relapsed and/or refractory multiple myeloma (MM). These data were reported in an oral presentation during the annual meeting of the American Society of Clinical Oncology (ASCO), held May 31st to June 4th in Chicago, Illinois.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES